低场磁共振成像技术在多囊肾病大鼠模型肾脏体积活体检测中的应用
|
摘要
目的利用低场磁共振技术测量多囊肾病大鼠的肾脏体积,探讨其在多囊肾病基础研究中的应用价值。方法将15只不同月龄的多囊肾病模型Han:SPRD大鼠麻醉后,利用低场磁共振技术测量其肾脏体积。肾脏轮廓由临床医师和设备工程师共同圈定,成像方法为T1加权成像,成像位置为肾脏横断面,利用图像处理软件计算肾脏体积。采用Pearson相关分析研究磁共振测量肾脏体积与解剖后实测体积、肾脏质量、肾脏质量/体质量比值、肾功能指标和囊肿指数的相关性。结果低场磁共振能够清晰地观察到Han:SPRD大鼠的肾脏,15只大鼠的磁共振测量体积分别为1.51、1.77、3.54、6.45、9.34、9.38、3.72、9.51、4.95、5.31、6.47、7.01、5.39、5.08、7.31 cm3,解剖后实测体积分别为1.50、1.70、2.90、5.00、7.00、7.02、2.50、7.10、4.70、4.90、6.50、6.70、4.20、4.90、7.00 cm3。磁共振测量肾脏体积与解剖后实测体积具有高度相关性(拟合优度R2为0.903 1),与肾脏质量、肾脏质量/体质量比值也存在较高的相关性(R2分别为0.912 8、0.777 9),与血清肌酐、尿素氮及囊肿指数均呈正相关(相关系数分别为0.86、0.85、0.61)。结论低场磁共振技术能够满足多囊肾病大鼠模型肾脏体积活体检测的需求,为多囊肾病的基础研究提供参考依据。
Objective To measure the renal volume of polycystic kidney disease rats using low ?eld magnetic resonance imaging(MRI), and to explore its application value in the basic research of polycystic kidney disease. Methods Fifteen Han: SPRD rats with polycystic kidney disease of different ages were subjected to anesthesia, and the kidney volume was measured using low ?eld MRI. The kidney pro?le was delineated by engineers and clinicians. The imaging method was T1-weighted imaging.The cross section of the kidney was imaged, and the kidney volume was calculated using image processing software. Pearson correlation analysis was used to analyze the correlation between the kidney volume measured by MRI and anatomical volume after dissection, kidney mass, the ratio of kidney mass to body mass, renal function indexes and cyst index. Results The kidney of Han:SPRD rats was clearly observed with low ?eld MRI. The kidney volumes of 15 rats measured by MRI were 1.51, 1.77, 3.54, 6.45,9.34, 9.38, 3.72, 9.51, 4.95, 5.31, 6.47, 7.01, 5.39, 5.08, and 7.31 cm3, respectively. The anatomical volumes after dissection were1.50, 1.70, 2.90, 5.00, 7.00, 7.02, 2.50, 7.10, 4.70, 4.90, 6.50, 6.70, 4.20, 4.90, and 7.00 cm3, respectively. The renal volume measured by MRI was highly correlated with the anatomical volume after dissection, kidney mass and the ratio of kidney mass to body mass(goodness of ?t [R2] was 0.903 1, 0.912 8 and 0.777 9, respectively), and was also positively correlated with serum creatinine, urea nitrogen and cyst index(correlation coef?cients were 0.86, 0.85 and 0.61, respectively). Conclusion Low ?eld MRI can be used to measure kidney volume of polycystic kidney disease rat models in vivo, providing a reference for the basic research of polycystic kidney disease.
Objective To measure the renal volume of polycystic kidney disease rats using low ?eld magnetic resonance imaging(MRI), and to explore its application value in the basic research of polycystic kidney disease. Methods Fifteen Han: SPRD rats with polycystic kidney disease of different ages were subjected to anesthesia, and the kidney volume was measured using low ?eld MRI. The kidney pro?le was delineated by engineers and clinicians. The imaging method was T1-weighted imaging.The cross section of the kidney was imaged, and the kidney volume was calculated using image processing software. Pearson correlation analysis was used to analyze the correlation between the kidney volume measured by MRI and anatomical volume after dissection, kidney mass, the ratio of kidney mass to body mass, renal function indexes and cyst index. Results The kidney of Han:SPRD rats was clearly observed with low ?eld MRI. The kidney volumes of 15 rats measured by MRI were 1.51, 1.77, 3.54, 6.45,9.34, 9.38, 3.72, 9.51, 4.95, 5.31, 6.47, 7.01, 5.39, 5.08, and 7.31 cm3, respectively. The anatomical volumes after dissection were1.50, 1.70, 2.90, 5.00, 7.00, 7.02, 2.50, 7.10, 4.70, 4.90, 6.50, 6.70, 4.20, 4.90, and 7.00 cm3, respectively. The renal volume measured by MRI was highly correlated with the anatomical volume after dissection, kidney mass and the ratio of kidney mass to body mass(goodness of ?t [R2] was 0.903 1, 0.912 8 and 0.777 9, respectively), and was also positively correlated with serum creatinine, urea nitrogen and cyst index(correlation coef?cients were 0.86, 0.85 and 0.61, respectively). Conclusion Low ?eld MRI can be used to measure kidney volume of polycystic kidney disease rat models in vivo, providing a reference for the basic research of polycystic kidney disease.
引文
[1]R O D R I G U E Z D,K A P O O R S,E D E N H O F E R I,SEGERER S,RIWANTO M,KIPAR A,et al.Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han:SPRD rats with polycystic kidney disease[J].Kidney Blood Press Res,2015,40:638-647.
[2]GALLIANI M,CHICCA S,VITALIANO E,DI LULLOL,GIANNAKAKIS K,PAONE A.[Renal manifestation of autosomal dominant polycystic kidney disease][J].G Ital Nefrol,2018,35.pii:2018-vol2.
[3]SUTTERS M,GERMIND C G.Autosomal dominant polycystic kidney disease:molecular genetics and pathophysiology[J].J Lab Clin Med,2003,141:91-101.
[4]ONG A C,DEVUYST O,KNEBELMANN B,WALZG;ERA-EDTA Working Group for Inherited Kidney Diseases.Autosomal dominant polycystic kidney disease:the changing face of clinical management[J].Lancet,2015,385:1993-2002.
[5]YAO Q,WU M,ZHOU J,ZHOU M,CHEN D,FUL,et al.Treatment of persistent gross hematuria with tranexamic acid in autosomal dominant polycystic kidney disease[J].Kidney Blood Press Res,2017,42:156-164.
[6]HARSKAMP L R,GANSEVOORT R T,BOERTIEN WE,VAN OEVEREN W,ENGELS G E,VAN GOOR H,et al.Urinary EGF receptor ligand excretion in patients with autosomal dominant polycystic kidney disease and response to tolvaptan[J].Clin J Am Soc Nephrol,2015,10:1749-1756.
[7]XUE C,ZHOU C,MEI C.Total kidney volume:the most valuable predictor of autosomal dominant polycystic kidney disease progression[J].Kidney Int,2018,93:540-542.
[8]GRANTHAM J J,COOK L T,TORRES V E,BOST J E,CHAPMAN A B,HARRIS P C,et al.Determinants of renal volume in autosomal-dominant polycystic kidney disease[J].Kidney Int,2008,73:108-116.
[9]N A N TAV I S H I T J,C H AT S U D T H I P O N G V,SOODVILAI S.Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion[J].Biochem Pharmacol,2018,154:175-182.
[10]YANG Y,CHEN M,ZHOU J,LV J,SONG S,FU L,et al.Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in Pkd1-deficient mice[J].J Am Soc Nephrol,2018,29:2310-2325.
[11]HIGASHIHARA E,NUTAHARA K,OKEGAWA T,TANBO M,HARA H,MIYAZAKI I,et al.Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease[J].Nephron,2015,129:253-262.
[12]LEONHARD W N,ZANDBERGEN M,VERAAR K,VAN DEN BERG S,VAN DER WEERD L,BREUNINGM,et al.Scattered deletion of PKD1 in kidneys causes a cystic snowball effect and recapitulates polycystic kidney disease[J].J Am Soc Nephrol,2015,26:1322-1333.
[13]SHIN D,LEE K B,HYUN Y Y,LEE Y R,HWANG YH,PARK H C,et al.Novel three-dimensional imaging volumetry in autosomal dominant polycystic kidney disease:comparison with 2D volumetry[J].Clin Nephrol,2014,82:98-106.
[14]CHEN Y,GU H,ZHANG D S,LI F,LIU T,XIA W.Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier[J].Biomaterials,2014,35:10058-10069.
[15]ZHAO J Y,CHEN G,GU Y P,CUI R,ZHANG Z L,YU ZL,et al.Ultrasmall magnetically engineered Ag2Se quantum dots for instant efficient labeling and whole-body highresolution multimodal real-time tracking of cell-derived microvesicles[J].J Am Chem Soc,2016,138:1893-1903.
[16]YIN J,BAO L,TIAN H,WANG Q,GAO X,YAOW.Genetic fusion of human FGF21 to a synthetic p o l y p e p t i d e i m p r o v e s p h a r m a c o k i n e t i c s a n d pharmacodynamics in a mouse model of obesity[J].Br JPharmacol,2016,173:2208-2223.
[17]CORSI C,MIGNANI R,TURCO D,MAGISTRONIR,SEVERI S.Comment on the paper:‘novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease’[J].Am J Nephrol,2014,39:163-164.
[2]GALLIANI M,CHICCA S,VITALIANO E,DI LULLOL,GIANNAKAKIS K,PAONE A.[Renal manifestation of autosomal dominant polycystic kidney disease][J].G Ital Nefrol,2018,35.pii:2018-vol2.
[3]SUTTERS M,GERMIND C G.Autosomal dominant polycystic kidney disease:molecular genetics and pathophysiology[J].J Lab Clin Med,2003,141:91-101.
[4]ONG A C,DEVUYST O,KNEBELMANN B,WALZG;ERA-EDTA Working Group for Inherited Kidney Diseases.Autosomal dominant polycystic kidney disease:the changing face of clinical management[J].Lancet,2015,385:1993-2002.
[5]YAO Q,WU M,ZHOU J,ZHOU M,CHEN D,FUL,et al.Treatment of persistent gross hematuria with tranexamic acid in autosomal dominant polycystic kidney disease[J].Kidney Blood Press Res,2017,42:156-164.
[6]HARSKAMP L R,GANSEVOORT R T,BOERTIEN WE,VAN OEVEREN W,ENGELS G E,VAN GOOR H,et al.Urinary EGF receptor ligand excretion in patients with autosomal dominant polycystic kidney disease and response to tolvaptan[J].Clin J Am Soc Nephrol,2015,10:1749-1756.
[7]XUE C,ZHOU C,MEI C.Total kidney volume:the most valuable predictor of autosomal dominant polycystic kidney disease progression[J].Kidney Int,2018,93:540-542.
[8]GRANTHAM J J,COOK L T,TORRES V E,BOST J E,CHAPMAN A B,HARRIS P C,et al.Determinants of renal volume in autosomal-dominant polycystic kidney disease[J].Kidney Int,2008,73:108-116.
[9]N A N TAV I S H I T J,C H AT S U D T H I P O N G V,SOODVILAI S.Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion[J].Biochem Pharmacol,2018,154:175-182.
[10]YANG Y,CHEN M,ZHOU J,LV J,SONG S,FU L,et al.Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in Pkd1-deficient mice[J].J Am Soc Nephrol,2018,29:2310-2325.
[11]HIGASHIHARA E,NUTAHARA K,OKEGAWA T,TANBO M,HARA H,MIYAZAKI I,et al.Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease[J].Nephron,2015,129:253-262.
[12]LEONHARD W N,ZANDBERGEN M,VERAAR K,VAN DEN BERG S,VAN DER WEERD L,BREUNINGM,et al.Scattered deletion of PKD1 in kidneys causes a cystic snowball effect and recapitulates polycystic kidney disease[J].J Am Soc Nephrol,2015,26:1322-1333.
[13]SHIN D,LEE K B,HYUN Y Y,LEE Y R,HWANG YH,PARK H C,et al.Novel three-dimensional imaging volumetry in autosomal dominant polycystic kidney disease:comparison with 2D volumetry[J].Clin Nephrol,2014,82:98-106.
[14]CHEN Y,GU H,ZHANG D S,LI F,LIU T,XIA W.Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier[J].Biomaterials,2014,35:10058-10069.
[15]ZHAO J Y,CHEN G,GU Y P,CUI R,ZHANG Z L,YU ZL,et al.Ultrasmall magnetically engineered Ag2Se quantum dots for instant efficient labeling and whole-body highresolution multimodal real-time tracking of cell-derived microvesicles[J].J Am Chem Soc,2016,138:1893-1903.
[16]YIN J,BAO L,TIAN H,WANG Q,GAO X,YAOW.Genetic fusion of human FGF21 to a synthetic p o l y p e p t i d e i m p r o v e s p h a r m a c o k i n e t i c s a n d pharmacodynamics in a mouse model of obesity[J].Br JPharmacol,2016,173:2208-2223.
[17]CORSI C,MIGNANI R,TURCO D,MAGISTRONIR,SEVERI S.Comment on the paper:‘novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease’[J].Am J Nephrol,2014,39:163-164.